Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Obama Taps Daschle, Lambrew To Lead Health Care Reform Office

This article was originally published in The Gray Sheet

Executive Summary

Tom Daschle, the former Democratic senator from South Dakota, and Jeanne Lambrew, a health policy expert from the Clinton Administration, will serve as director and deputy director of a newly created White House Office of Health Care Reform, President-elect Barack Obama announced Dec. 11

You may also be interested in...



Obama Health Team: Califf Out Of FDA Search; Lambrew Likely To Leave Post

The make-up of the health policy leadership within the Obama administration remains in limbo, but recent developments suggest choices for some key positions may be near

Obama Health Team: Califf Out Of FDA Search; Lambrew Likely To Leave Post

The make-up of the health policy leadership within the Obama administration remains in limbo, but recent developments suggest choices for some key positions may be near

HHS Secretary Daschle, OMB Director Orszag Set Tone For Health Reform

President-elect Barack Obama's selections of Tom Daschle for HHS secretary and current Congressional Budget Office Director Peter Orszag as head of the Office of Management and Budget accomplish at least two goals - it brings in a seasoned legislative strategist as the administration gets set to embark on health care reform and also reins in one of the party's most outspoken thinkers

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026898

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel